Actinium Pharmaceuticals
Actinium Pharmaceuticals
ATNM
NYSE
1.21
USD
8.04%
About
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A.
Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes.
The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 524.7K |
| Three Month Average Volume | 16.7M |
| High Low | |
| Fifty-Two Week High | 10.24 USD |
| Fifty-Two Week Low | 1.33 USD |
| Fifty-Two Week High Date | 14 May 2024 |
| Fifty-Two Week Low Date | 05 Aug 2024 |
| Price and Volume | |
| Current Price | 1.99 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -69.47% |
| Thirteen Week Relative Price Change | -77.19% |
| Twenty-Six Week Relative Price Change | -78.63% |
| Fifty-Two Week Relative Price Change | -73.58% |
| Year-to-Date Relative Price Change | -66.92% |
| Price Change | |
| One Day Price Change | 4.19% |
| Thirteen Week Price Change | -75.58% |
| Twenty-Six Week Price Change | -76.51% |
| Five Day Price Change | -1.00% |
| Fifty-Two Week Price Change | -66.89% |
| Year-to-Date Price Change | -60.83% |
| Month-to-Date Price Change | -71.24% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.31645 USD |
| Book Value Per Share (Most Recent Quarter) | 1.43483 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.31645 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.43483 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.63252 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00304 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00288 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.83498 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.51862 USD |
| Normalized (Last Fiscal Year) | -1.83498 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.83498 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.51862 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.83498 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.51862 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.77471 USD |
| Cash Per Share (Most Recent Quarter) | 2.81621 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.80529 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.48721 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.20922 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -4,594 |
| Cash Flow Revenue (Trailing Twelve Months) | -41,978 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -52,620.99% |
| Pretax Margin (Last Fiscal Year) | -60,269.14% |
| Pretax Margin (5 Year) | -6,683.95% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -64,098.77% |
| Operating Margin (Trailing Twelve Months) | -57,665.43% |
| Operating Margin (5 Year) | -6,893.68% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -60,269.14% |
| Net Profit Margin (Trailing Twelve Months) | -52,620.99% |
| Net Profit Margin (5 Year) | -6,683.95% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -10.44% |
| Tangible Book Value (5 Year) | 32.78% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 80.00% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 9.75% |
| Total Debt (5 Year) | -35.20% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 34.87% |
| EPS Change (Trailing Twelve Months) | 15.76% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -86,012,000 |
| Net Debt (Last Fiscal Year) | -76,647,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 765 |
| Price to Sales (Trailing Twelve Months) | 765 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 9 |
| Current Ratio (Most Recent Quarter) | 9 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -47,488,000 |
| Free Cash Flow (Trailing Twelve Months) | -34,002,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -49.91% |
| Return on Assets (Trailing Twelve Months) | -45.12% |
| Return on Assets (5 Year) | -46.98% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -94.92% |
| Return on Equity (Trailing Twelve Months) | -87.96% |
| Return on Equity (5 Year) | -65.65% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -55.31% |
| Return on Investment (Trailing Twelve Months) | -50.13% |
| Return on Investment (5 Year) | -52.71% |